C07C 307/10
Having nitrogen atoms of the sulfamide groups bound to carbon atoms of
Official title: having nitrogen atoms of the sulfamide groups bound to carbon atoms of six-membered aromatic rings
C07C307/10 (Having nitrogen atoms of the sulfamide groups bound to carbon atoms of) appears on 100 US grants and 106 published applications in this corpus.
Search patents in C07C- Granted patents
- 100
- Published applications
- 106
- Assignees
- 64
- Inventors
- 356
- Latest grant
- 21 Apr 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1977 | 1 | 0 |
| 1978 | 6 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 1 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 2 | 0 |
| 1994 | 3 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 2 | 0 |
| 1998 | 3 | 0 |
| 1999 | 2 | 0 |
| 2000 | 1 | 0 |
| 2001 | 5 | 0 |
| 2002 | 2 | 7 |
| 2003 | 4 | 2 |
| 2004 | 1 | 6 |
| 2005 | 3 | 4 |
| 2006 | 2 | 2 |
| 2007 | 5 | 5 |
| 2008 | 4 | 6 |
| 2009 | 3 | 8 |
| 2010 | 2 | 6 |
| 2011 | 3 | 4 |
| 2012 | 3 | 6 |
| 2013 | 4 | 5 |
| 2014 | 3 | 8 |
| 2015 | 4 | 1 |
| 2016 | 3 | 4 |
| 2017 | 5 | 8 |
| 2018 | 4 | 4 |
| 2019 | 4 | 4 |
| 2020 | 3 | 2 |
| 2021 | 3 | 2 |
| 2022 | 1 | 1 |
| 2023 | 1 | 2 |
| 2024 | 3 | 4 |
| 2025 | 3 | 4 |
| 2026 | 1 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives21 Apr 2026US 12,606,522 B2OrsoBio, Inc.
- Phenylalanine-based LAT1 inhibitors and uses thereof30 Sep 2025US 12,427,124 B1Maxymune Therapeutics, Inc.
- 17-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereof12 Aug 2025US 12,384,753 B2Enanta Pharmaceuticals, Inc.
- Pyruvate kinase activators for use in therapy5 Aug 2025US 12,377,093 B2Agios Pharmaceuticals, Inc.
- Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives30 Jul 2024US 12,049,439 B2OrsoBio, Inc.
- Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives16 Jul 2026US 2026/0200844 A1OrsoBio, Inc.
- 17-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors and Methods of Use Thereof11 Dec 2025US 2025/0376452 A1Enanta Pharmaceuticals, Inc.
- Phenylalanine-based lat1 inhibitors and uses thereof6 Nov 2025US 2025/0339388 A1Maxymune Therapeutics, Inc.
- Pyruvate kinase activators for use in therapy30 Oct 2025US 2025/0332161 A1Agios Pharmaceuticals, Inc.
- Phenylalanine-based lat1 inhibitors and uses thereof16 Oct 2025US 2025/0319046 A1Maxymune Therapeutics, Inc.
Most cited
By later US patents
- IL-8 receptor antagonists92US 5,886,044 ASmithKline Beecham Corporation · 1999
- IL-8 receptor antagonists88US 5,780,483 ASmithKline Beecham Corporation · 1998
- IL-8 receptor antagonists76US 6,262,113 B1SmithKline Beecham Corporation · 2001
- Glucocorticoid receptor modulators52US 6,583,180 B2Abbott Laboratories · 2003
- LXR modulators44US 6,316,503 B1Tularik Inc. · 2001